Literature DB >> 16442929

Epidemiologic, clinical, and microbiologic profile of infective endocarditis in Argentina: a national survey. The Endocarditis Infecciosa en la República Argentina-2 (EIRA-2) Study.

Ernesto Ferreiros1, Francisco Nacinovich, Jose Horacio Casabé, Juan Carlos Modenesi, Sandra Swieszkowski, Claudia Cortes, Cohen Arazi Hernan, Lucía Kazelian, Sergio Varini.   

Abstract

BACKGROUND: This study aimed to determine the epidemiologic, clinical, microbiologic characteristics, and inhospital outcome of infective endocarditis (IE) in Argentina and compare the results with those of the 1992 IE national survey.
METHODS: A prospective, multicenter study was conducted in 82 hospitals representing 16 of 24 provinces of Argentina. Patients with diagnosis of IE according to the Duke criteria were surveyed during an 18-month period.
RESULTS: From 470 surveyed episodes of IE, 390 cases were classified as definite and 80 as possible IE. The mean age of the definite IE cases was 58.5 +/- 17.3 years; male sex, 70.0%; and male-female ratio, 2.3:1. Pathological evidence of IE was available in 26.2%. There was no previously known heart disease in 35.1%, and the proportion of prosthetic valve IE was 15.9%. Causative microorganisms were streptococci, 38.3% (Streptococcus viridans 27.0%, Streptococcus bovis 5.2%, others 6.1%); enterococci, 10.2%; staphylococci, 36.7% (Staphylococcus aureus 29.8%, coagulase-negative staphylococci 6.9%); HACEK group, 6.1%; fungal, 1.4%; and polymicrobial, 2.0%. Blood culture results were negative in 10.8%. Surgical treatment was performed in 26.2%, and the overall inhospital mortality was 24.6%. Patients from the 2002 survey were older (58.5 +/- 17.3 vs 51.3 +/- 18.7 years, P < .01) and more frequently had underlying heart disease (64.9% vs 55.0%, P < .01): degenerative valve disease (11.5% vs 4.8%, P < .01), congenital heart disease (9.5% vs 4.2%, P < .01), and prosthetic valve IE (15.9% vs 8.5%, P < .01). Conversely, the prevalence of rheumatic valve disease was significantly less than in the 1992 survey (5.4% vs 13.0%, P < .01).
CONCLUSIONS: The EIRA-2 survey shows that the clinical profile of IE has changed in Argentina. Currently, patients with IE are older and have a higher frequency of underlying heart disease, degenerative valve disease, and prosthetic valve IE than previously. The incidence of staphylococcal IE has increased. Inhospital mortality remains high, suggesting that more aggressive measures are needed for the early identification, prevention, and treatment of IE.

Entities:  

Mesh:

Year:  2006        PMID: 16442929     DOI: 10.1016/j.ahj.2005.04.008

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  25 in total

Review 1.  The Changing Epidemiology of Infective Endocarditis in the Twenty-First Century.

Authors:  J Ambrosioni; M Hernandez-Meneses; A Téllez; J Pericàs; C Falces; J M Tolosana; B Vidal; M Almela; E Quintana; J Llopis; A Moreno; José M Miro
Journal:  Curr Infect Dis Rep       Date:  2017-05       Impact factor: 3.725

2.  Infective endocarditis in a Finnish teaching hospital: a study on 326 episodes treated during 1980-2004.

Authors:  M Heiro; H Helenius; S Mäkilä; U Hohenthal; T Savunen; E Engblom; J Nikoskelainen; P Kotilainen
Journal:  Heart       Date:  2006-04-27       Impact factor: 5.994

3.  Health Care-Associated Infective Endocarditis: a Growing Entity that Can Be Prevented.

Authors:  Natividad Benito; Juan M Pericas; Mercè Gurguí; Carlos A Mestres; Francesc Marco; Asunción Moreno; Juan P Horcajada; José M Miró
Journal:  Curr Infect Dis Rep       Date:  2014-11       Impact factor: 3.725

Review 4.  The causative agents in infective endocarditis: a systematic review comprising 33,214 cases.

Authors:  Christiana T Vogkou; Nikolaos I Vlachogiannis; Leonidas Palaiodimos; Antonis A Kousoulis
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-05-11       Impact factor: 3.267

5.  Infective endocarditis in Rio de Janeiro, Brazil: a 5-year experience at two teaching hospitals.

Authors:  P V Damasco; J N Ramos; J C D Correal; M V Potsch; V V Vieira; T C F Camello; M P Pereira; V D Marques; K R N Santos; E A Marques; M B Castier; R Hirata; A L Mattos-Guaraldi; C Q Fortes
Journal:  Infection       Date:  2014-06-17       Impact factor: 3.553

6.  Clinical features and outcome of infective endocarditis in yemeni patients treated with empirical antibiotic therapy.

Authors:  Al-Aghbari Khaled; Alezzy Yahya Al-Noami; Mohamed Al-Ansi; Ahmed Askar Faiza
Journal:  Heart Views       Date:  2010-03

7.  Are histopathological findings of diagnostic value in native valve endocarditis?

Authors:  F Zauner; T Glück; B Salzberger; B Ehrenstein; G Beutel; F Robl; F Hanses; D Birnbaum; H J Linde; F Audebert
Journal:  Infection       Date:  2013-02-02       Impact factor: 3.553

8.  Clinical and microbiological profiles of infective endocarditis in a tertiary hospital in Aseer region, Saudi Arabia.

Authors:  Abdullah S Assiri
Journal:  J Saudi Heart Assoc       Date:  2011-04-21

9.  Health care-associated native valve endocarditis: importance of non-nosocomial acquisition.

Authors:  Natividad Benito; José M Miró; Elisa de Lazzari; Christopher H Cabell; Ana del Río; Javier Altclas; Patrick Commerford; Francois Delahaye; Stefan Dragulescu; Helen Giamarellou; Gilbert Habib; Adeeba Kamarulzaman; A Sampath Kumar; Francisco M Nacinovich; Fredy Suter; Christophe Tribouilloy; Krishnan Venugopal; Asuncion Moreno; Vance G Fowler
Journal:  Ann Intern Med       Date:  2009-05-05       Impact factor: 25.391

10.  HACEK infective endocarditis: characteristics and outcomes from a large, multi-national cohort.

Authors:  Stephen T Chambers; David Murdoch; Arthur Morris; David Holland; Paul Pappas; Manel Almela; Nuria Fernández-Hidalgo; Benito Almirante; Emilio Bouza; Davide Forno; Ana del Rio; Margaret M Hannan; John Harkness; Zeina A Kanafani; Tahaniyat Lalani; Selwyn Lang; Nigel Raymond; Kerry Read; Tatiana Vinogradova; Christopher W Woods; Dannah Wray; G Ralph Corey; Vivian H Chu
Journal:  PLoS One       Date:  2013-05-17       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.